search
Back to results

Exparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain

Primary Purpose

Pain, Postoperative, Opioid Use, Perioperative Complication

Status
Not yet recruiting
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
bupivacaine liposome injectable suspension
Bupivacaine Hydrochloride
Sponsored by
Rutgers, The State University of New Jersey
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Postoperative focused on measuring plane block, sternotomy, thoracotomy, cardiac, surgery, postoperative, pain, anesthesia, opioid, pragmatic trial

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adults (18 years-no upper age limit) Scheduled for mini thoracotomy (i.e. valve repair) or open sternotomy (i.e. bypass graft) at single academic medical center (in and out-patients). Exclusion Criteria: Patients will be excluded if they: Are currently on pain medication or pain regimen Convert to open heart procedure (for thoracotomies) Require additional procedure then originally scheduled Undergo emergent surgery Are non-English speaking (The majority of the PI's patient population speak English. As a pilot study we cannot afford the time, effort or money to enroll non-English speaking subjects.)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Exparel

    Marcaine

    Arm Description

    The experimental medication (Exparel) will be administered per standard of care via ultrasound-guided erector spinae plane (ESP) blocks, bilaterally for sternotomy and unilaterally for mini-thoracotomy. The drug will be administered prior to cardiac surgery. The dosage will be determined by patient body weight. For this pilot project we anticipate consenting 120 subjects to obtain 96 evaluable subjects; 48 Mini thoractomies (N=24 Exparel, N=24 Marcaine) 48Open sternotomies (N=24 Exparel, N=24 Marcaine).

    The active comparitor medication (Marcaine) will be administered per standard of care via ultrasound-guided erector spinae plane (ESP) blocks, bilaterally for sternotomy and unilaterally for mini-thoracotomy. The drug will be administered prior to cardiac surgery. The dosage will be determined by patient body weight. For this pilot project we anticipate consenting 120 subjects to obtain 96 evaluable subjects; 48 Mini thoractomies (N=24 Exparel, N=24 Marcaine) 48Open sternotomies (N=24 Exparel, N=24 Marcaine).

    Outcomes

    Primary Outcome Measures

    Postoperative opioid consumption
    Postoperative opioid consumption within first five postoperative days, reported as average mg/day in morphine equivalents.
    Postoperative nonopioid analgesic consumption
    Postoperative nonopioid analgesic (Pregabalin, Gabapentin, SSRI/SNRI, Ketorolac, Tramadol, Ibuprofin, and Acetaminophen) consumption within first five postoperative days, reported as average mg/day in morphine equivalents.

    Secondary Outcome Measures

    Inpatient postoperative pain score
    Pain scores through postoperative day five, reported as mean score (1-10, 10 most severe) over all five days.
    Outpatient postoperative pain score
    Single pain score at follow-up visit
    30-day outcomes
    Postoperative complications and outcomes (composite of all-cause mortality and major morbidity): Pneumonia, Respiratory failure with ventilatory support >48h, Pulmonary embolism, DVT, Organ Failure, Postop MI, Renal replacement therapy, Infection of wound or line, Readmission, Postoperative Arrhythmia, Postoperative atrial fibrillation, death
    Postoperative qualify of life
    Measured as change on SF-12 survey from preoperative baseline to followup.
    Hospitalization cost
    Before-insurance cost of hospitalization and treatment.

    Full Information

    First Posted
    July 15, 2023
    Last Updated
    October 4, 2023
    Sponsor
    Rutgers, The State University of New Jersey
    Collaborators
    Pacira Pharmaceuticals, Inc
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06077422
    Brief Title
    Exparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain
    Official Title
    Randomized Control Trial to Assess the Efficacy of Preoperative Erector Spinae Blocks on Cardiac Surgery Postoperative Outcomes
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 2, 2024 (Anticipated)
    Primary Completion Date
    January 2, 2025 (Anticipated)
    Study Completion Date
    April 5, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Rutgers, The State University of New Jersey
    Collaborators
    Pacira Pharmaceuticals, Inc

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    Yes
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The goal of this pilot study is to describe and compare Ultrasound-Guided Erector Spinae Plane (ESP) Blocks using Exparel® (bupivacaine liposome injectable suspension) to Marcaine® (bupivacaine hydrochloride) for pain management and outcomes after cardiac surgeries.
    Detailed Description
    Postoperative pain is a major concern for patients after cardiovascular surgery. With an increasing emphasis on improving perioperative care arising from evidence-based protocols such as Enhanced Recovery After Surgery (ERAS), reducing postoperative pain not only increases patient satisfaction, but also decreases postoperative complications and improves outcomes. Reduced postoperative pain also decreases rates of pneumonia and time on mechanical ventilation, in the ICU, or in the hospital. Importantly, decreasing postoperative pain can also reduce high dose opioid usage, the established method of managing postoperative pain, thereby decreasing rates of nausea/vomiting, intubation time, and mortality. Methods of reducing postoperative pain, such as neuraxial anesthesia and deep plexus blocks, are associated with an increased risk of epidural hematoma; an alternate solution, therefore, is using fascial plane blocks. Since 2018, our institution is one of very few that uses pre-operative fascial plane blocks for cardiac surgery patients, implementing bilateral plane blocks for the sternotomy approach and unilateral plane blocks for the right mini-thoracotomy approach. Results from these blocks have been quite favorable but not yet validated. It would be unethical to do a study in which subjects are randomized to not receive the block preoperatively. Therefore, this study is designed to better understand the overall effects of these blocks by comparing FDA approved medications, Exparel (current practice at RWJUH) and Marcaine. Marcaine (0.25% bupivacaine HCl) has an onset of action on the order of seconds and generally within one minute from the time of injection, and an effect duration of roughly seven hours. Exparel is a commercially available extended-release formulation of liposomal bupivacaine, which extends the effect duration to an upward of 72 hours from the time of injection with similarly immediate onset of action. Several studies have compared local injections of Marcaine (plain bupivacaine) with Exparel (liposomal bupivacaine) in the setting of inguinal hernia repair, knee arthroplasty, breast augmentation, and hemorrhoidectomy, with results favoring the use of liposomal bupivacaine based on improvements in subjective pain at the initial postoperative pain assessment.(6) Clinical trials are currently underway, investigating the effect of liposomal bupivacaine for local anesthesia and compared with epidural anesthesia in thoracoscopic surgery. In a recent clinical trial published in JAMA, patients undergoing cardiothoracic or vascular surgery subjected to truncal incisions did not demonstrate a significant benefit with respect to pain control or adjunctive opioid usage when treated with liposomal bupivacaine over plain bupivacaine via local injection. Still, a gap in the literature exists with respect to the use of liposomal bupivacaine versus plain bupivacaine for erector spinae plane block in the setting of sternotomy. The aim of this prospective study is to determine the impact of preoperative fascial plane blocks with Exparel compared to Marcaine on outcomes following cardiac procedures.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pain, Postoperative, Opioid Use, Perioperative Complication, Heart Diseases
    Keywords
    plane block, sternotomy, thoracotomy, cardiac, surgery, postoperative, pain, anesthesia, opioid, pragmatic trial

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2, Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    120 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Exparel
    Arm Type
    Experimental
    Arm Description
    The experimental medication (Exparel) will be administered per standard of care via ultrasound-guided erector spinae plane (ESP) blocks, bilaterally for sternotomy and unilaterally for mini-thoracotomy. The drug will be administered prior to cardiac surgery. The dosage will be determined by patient body weight. For this pilot project we anticipate consenting 120 subjects to obtain 96 evaluable subjects; 48 Mini thoractomies (N=24 Exparel, N=24 Marcaine) 48Open sternotomies (N=24 Exparel, N=24 Marcaine).
    Arm Title
    Marcaine
    Arm Type
    Active Comparator
    Arm Description
    The active comparitor medication (Marcaine) will be administered per standard of care via ultrasound-guided erector spinae plane (ESP) blocks, bilaterally for sternotomy and unilaterally for mini-thoracotomy. The drug will be administered prior to cardiac surgery. The dosage will be determined by patient body weight. For this pilot project we anticipate consenting 120 subjects to obtain 96 evaluable subjects; 48 Mini thoractomies (N=24 Exparel, N=24 Marcaine) 48Open sternotomies (N=24 Exparel, N=24 Marcaine).
    Intervention Type
    Drug
    Intervention Name(s)
    bupivacaine liposome injectable suspension
    Other Intervention Name(s)
    Exparel
    Intervention Description
    Bupivacaine liposome injectable suspension (Exparel) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
    Intervention Type
    Drug
    Intervention Name(s)
    Bupivacaine Hydrochloride
    Other Intervention Name(s)
    Marcaine
    Intervention Description
    Bupivacaine HCl (Marcaine) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
    Primary Outcome Measure Information:
    Title
    Postoperative opioid consumption
    Description
    Postoperative opioid consumption within first five postoperative days, reported as average mg/day in morphine equivalents.
    Time Frame
    Postoperative days 0 through 5
    Title
    Postoperative nonopioid analgesic consumption
    Description
    Postoperative nonopioid analgesic (Pregabalin, Gabapentin, SSRI/SNRI, Ketorolac, Tramadol, Ibuprofin, and Acetaminophen) consumption within first five postoperative days, reported as average mg/day in morphine equivalents.
    Time Frame
    Postoperative days 0 through 5
    Secondary Outcome Measure Information:
    Title
    Inpatient postoperative pain score
    Description
    Pain scores through postoperative day five, reported as mean score (1-10, 10 most severe) over all five days.
    Time Frame
    Postoperative days 0 through 5
    Title
    Outpatient postoperative pain score
    Description
    Single pain score at follow-up visit
    Time Frame
    Obtained within 30 days following surgery
    Title
    30-day outcomes
    Description
    Postoperative complications and outcomes (composite of all-cause mortality and major morbidity): Pneumonia, Respiratory failure with ventilatory support >48h, Pulmonary embolism, DVT, Organ Failure, Postop MI, Renal replacement therapy, Infection of wound or line, Readmission, Postoperative Arrhythmia, Postoperative atrial fibrillation, death
    Time Frame
    Through postoperative day 30
    Title
    Postoperative qualify of life
    Description
    Measured as change on SF-12 survey from preoperative baseline to followup.
    Time Frame
    Within the range of 30 days prior to surgery to 30 days after surgery
    Title
    Hospitalization cost
    Description
    Before-insurance cost of hospitalization and treatment.
    Time Frame
    Study duration, limited to one year.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adults (18 years-no upper age limit) Scheduled for mini thoracotomy (i.e. valve repair) or open sternotomy (i.e. bypass graft) at single academic medical center (in and out-patients). Exclusion Criteria: Patients will be excluded if they: Are currently on pain medication or pain regimen Convert to open heart procedure (for thoracotomies) Require additional procedure then originally scheduled Undergo emergent surgery Are non-English speaking (The majority of the PI's patient population speak English. As a pilot study we cannot afford the time, effort or money to enroll non-English speaking subjects.)
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Leonard Y Lee, MD
    Phone
    732-235-9220
    Email
    leele@rwjms.rutgers.edu
    First Name & Middle Initial & Last Name or Official Title & Degree
    Russell J Pepe, MD
    Email
    rpepe@rwjms.rutgers.edu
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Leonard Y Lee, MD
    Organizational Affiliation
    Rutgers Robert Wood Johnson Medical School, Dept of Surgery
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    35274774
    Citation
    Toscano A, Barbero C, Capuano P, Costamagna A, Pocar M, Trompeo A, Pasero D, Rinaldi M, Brazzi L. Chronic postsurgical pain and quality of life after right minithoracotomy mitral valve operations. J Card Surg. 2022 Jun;37(6):1585-1590. doi: 10.1111/jocs.16400. Epub 2022 Mar 11.
    Results Reference
    background
    PubMed Identifier
    30052229
    Citation
    Nagaraja PS, Ragavendran S, Singh NG, Asai O, Bhavya G, Manjunath N, Rajesh K. Comparison of continuous thoracic epidural analgesia with bilateral erector spinae plane block for perioperative pain management in cardiac surgery. Ann Card Anaesth. 2018 Jul-Sep;21(3):323-327. doi: 10.4103/aca.ACA_16_18.
    Results Reference
    background
    PubMed Identifier
    30665850
    Citation
    Macaire P, Ho N, Nguyen T, Nguyen B, Vu V, Quach C, Roques V, Capdevila X. Ultrasound-Guided Continuous Thoracic Erector Spinae Plane Block Within an Enhanced Recovery Program Is Associated with Decreased Opioid Consumption and Improved Patient Postoperative Rehabilitation After Open Cardiac Surgery-A Patient-Matched, Controlled Before-and-After Study. J Cardiothorac Vasc Anesth. 2019 Jun;33(6):1659-1667. doi: 10.1053/j.jvca.2018.11.021. Epub 2018 Nov 19.
    Results Reference
    background
    PubMed Identifier
    33046362
    Citation
    Song K, Xu Q, Knott VH, Zhao CB, Clifford SP, Kong M, Slaughter MS, Huang Y, Huang J. Liposomal Bupivacaine-Based Erector Spinae Block for Cardiac Surgery. J Cardiothorac Vasc Anesth. 2021 May;35(5):1555-1559. doi: 10.1053/j.jvca.2020.09.115. Epub 2020 Sep 20. No abstract available.
    Results Reference
    background
    PubMed Identifier
    24431939
    Citation
    Collins JB, Song J, Mahabir RC. Onset and duration of intradermal mixtures of bupivacaine and lidocaine with epinephrine. Can J Plast Surg. 2013 Spring;21(1):51-3. doi: 10.1177/229255031302100112.
    Results Reference
    background
    PubMed Identifier
    27347237
    Citation
    Gadsden J, Long WJ. Time to Analgesia Onset and Pharmacokinetics After Separate and Combined Administration of Liposome Bupivacaine and Bupivacaine HCl: Considerations for Clinicians. Open Orthop J. 2016 Apr 12;10:94-104. doi: 10.2174/1874325001610010094. eCollection 2016.
    Results Reference
    background
    PubMed Identifier
    33724391
    Citation
    Sandhu HK, Miller CC 3rd, Tanaka A, Estrera AL, Charlton-Ouw KM. Effectiveness of Standard Local Anesthetic Bupivacaine and Liposomal Bupivacaine for Postoperative Pain Control in Patients Undergoing Truncal Incisions: A Randomized Clinical Trial. JAMA Netw Open. 2021 Mar 1;4(3):e210753. doi: 10.1001/jamanetworkopen.2021.0753.
    Results Reference
    background
    Links:
    URL
    https://classic.clinicaltrials.gov/ct2/show/NCT03682224
    Description
    Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients (BEMP)
    URL
    https://clinicaltrials.gov/ct2/show/NCT02178553
    Description
    Study of Exparel Versus Epidural for Pain Control After Thoracotomy

    Learn more about this trial

    Exparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain

    We'll reach out to this number within 24 hrs